Prognostic Biomarkers for Patients with Early Stage Lung Cancer
Posted Jun 20 2013 8:00pm
Description of Invention: Investigators at the National Cancer Institute have discovered a set of biomarkers that can identify patients with early stage lung cancer who have a high risk of relapse. Available for licensing are prognostic assays based on these biomarkers, which can enable clinicians to select more effective therapy and post-operative follow-up strategies.
Surgery is the standard care for patients with stage I lung cancer. Despite successful surgery, 20-30% of patients will relapse. Chemotherapy can improve patient survival; however, it is controversial if early stage cancer patients should be treated with chemotherapy since, for many cases, it will harm quality of life with little therapeutic benefit. Utilizing patient samples, the investigators conducted a retrospective study in eight patient cohorts that validated the gene classifier set. These prognostic methods can guide physicians to select appropriate treatment and follow-up while sparing other patients of unnecessary treatment and negative side-effects of chemotherapy.
Method to determine the prognosis of patients with lung cancer.
Method to select more effective treatment and post-operative follow-up for patients with early stage lung cancer.
Advantages: Assays were validated in human tissue samples and eight different patient cohorts.
In vivo data available (human)
Inventors: Curtis C Harris (NCI) Aaron J Schetter (NCI) Ichiro Akagi (Nippon Medical School) Hirokazu Okayama (NCI)
Collaborative Research Opportunity: The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize an early detection test for lung cancer. For collaboration opportunities, please contact John Hewes, Ph.D. at email@example.com .
For Licensing Information Please Contact: Jennifer Wong NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-4633 Fax: 301-402-0220